Randomised vitamin E supplementation and risk of chronic lung disease in the Women's Health Study.
BACKGROUND
The oxidant/antioxidant balance in lung tissue is hypothesised to contribute to the risk of chronic obstructive pulmonary disease (COPD). Observational studies consistently report higher antioxidant status associated with lower COPD risk, but few randomised studies have been reported.


METHODS
A post hoc analysis of 38,597 women without chronic lung disease at baseline was conducted in the Women's Health Study (WHS) to test the effect of vitamin E on the risk of incident chronic lung disease. The WHS is a randomised double-blind placebo-controlled factorial trial of vitamin E (600 IU every other day) and aspirin (100 mg every other day) in female health professionals aged≥45 years. Using Cox proportional hazards models, the effect of randomised vitamin E assignment on self-reported physician-diagnosed chronic lung disease was evaluated.


RESULTS
During 10 years of follow-up (376,710 person-years), 760 first occurrences of chronic lung disease were reported in the vitamin E arm compared with 846 in the placebo arm (HR 0.90; 95% CI 0.81 to 0.99; p=0.029). This 10% reduction in the risk of incident chronic lung disease was not modified by cigarette smoking, age, randomised aspirin assignment, multivitamin use or dietary vitamin E intake (minimum p for interaction=0.19). Current cigarette smoking was a strong predictor of chronic lung disease risk (HR 4.17; 95% CI 3.70 to 4.70; vs. never smokers).


CONCLUSIONS
In this large randomised trial, assignment to 600 IU vitamin E led to a 10% reduction in the risk of chronic lung disease in women.
Cornell University, Ithaca, NY 14853, USA.
Anne H
AH
Agler
Tobias
T
Kurth
J Michael
JM
Gaziano
Julie E
JE
Buring
Patricia A
PA
Cassano
D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D019587:Dietary Supplements; D004334:Drug Administration Schedule; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000453:epidemiology / Q000517:prevention & control*; D008875:Middle Aged; D014481:United States / Q000453:epidemiology; D024502:alpha-Tocopherol / Q000008:administration & dosage / Q000627:therapeutic use*
D000975:Antioxidants; D024502:alpha-Tocopherol
Chest. 2009 Oct;136(4):1055-1062
19592473
Epidemiol Rev. 2001;23(2):268-87
12192737
Cell Mol Biol (Noisy-le-grand). 2009 Feb 25;55 Suppl:OL1111-20
19267994
Thorax. 1998 Mar;53(3):166-71
9659349
Am J Clin Nutr. 2007 Aug;86(2):488-95
17684223
Am J Clin Nutr. 2006 Nov;84(5):1200-7
17093175
Immunol Rev. 2005 Jun;205:269-84
15882360
Proc Nutr Soc. 1999 May;58(2):309-19
10466172
Lancet. 2002 Jul 6;360(9326):23-33
12114037
Respir Med. 2005 Jan;99(1):118-25
15672860
Crit Rev Food Sci Nutr. 2008 Sep;48(8):760-74
18756398
Am J Epidemiol. 2002 May 15;155(10):965-71
11994237
J Womens Health Gend Based Med. 2000 Jan-Feb;9(1):19-27
10718501
Nat Med. 1998 Nov;4(11):1241-3
9809543
Circulation. 2010 Mar 2;121(8):1033-44
20194876
J Biosci. 2003 Feb;28(1):7-11
12682418
Am J Epidemiol. 2002 May 1;155(9):842-8
11978588
Respir Res. 2008 Sep 29;9:67
18823528
Am J Respir Crit Care Med. 1997 Nov;156(5):1447-52
9372659
Eur Respir J. 2010 Oct;36(4):774-80
20150206
Clin Endocrinol (Oxf). 2009 Apr;70(4):561-8
18715284
Circulation. 2000 Nov 7;102(19):2347-52
11067787
BMJ. 2010 Nov 04;341:c5702
21051774
Clin Trials. 2009 Feb;6(1):28-41
19254931
Indian J Med Res. 2008 Dec;128(6):705-11
19246793
JAMA. 2005 Jul 6;294(1):56-65
15998891
Am J Respir Crit Care Med. 2002 Dec 15;166(12 Pt 2):S62-6
12471091
Am J Epidemiol. 2000 May 15;151(10):975-81
10853636
Ann Intern Med. 2005 Jan 4;142(1):37-46
15537682
Eur Respir J. 2006 Feb;27(2):397-412
16452599
Am J Cardiol. 2009 Feb 1;103(3):361-8
19166690
Int J Tuberc Lung Dis. 2008 Jul;12(7):703-8
18544191
J Asthma. 2006 Jan-Feb;43(1):75-80
16448970